Spruce Biosciences launched MPS3BStudy.com, a single place for families and caregivers to learn about the planned expanded access program for TA-ERT, the planned TrAnsform confirmatory study, and register interest.
Published
Signal category
Products & Services
Quote
“Lat week we launched MPS3BStudy.com — a single place where families and caregivers can learn about the planned expanded access program (EAP) for TA-ERT, the planned TrAnsform confirmatory study, and register interest in both.”
— Javier Szwarcberg|Spruce Biosciences team
Company
Spruce Biosciences
Where science meets compassion to deliver targeted therapies for serious neurological disorders.
- Industry
- Biotechnology Research
- Location
- South San Francisco, US
- Company size
- 38 employees
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. At the heart of everything we do is our commitment to patients and their families. They inspire us to go beyond incremental progress to develop transformative therapies born from thoughtful science that leads to meaningful changes in their lives. Our initial focus is developing tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of mucopolysaccharidoses type IIIB (MPS IIIB), or Sanfilippo Syndrome Type B, a devastating pediatric neurodegenerative disorder for which there are no FDA-approved therapies.
Founded 2016